Provided by Tiger Fintech (Singapore) Pte. Ltd.

PDS Biotechnology Corporation

1.26
+0.02001.61%
Volume:103.86K
Turnover:130.68K
Market Cap:57.20M
PE:-1.22
High:1.29
Open:1.24
Low:1.22
Close:1.24
Loading ...

PDS Biotech Announces FDA Clearance of Ind Application for Combination of Versamune® Muc1 and PDS01ADC to Treat Metastatic Colorectal Cancer

THOMSON REUTERS
·
13 Mar

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Mar

PDS Biotechnology initiates VERSATILE-003 Phase 3 trial of Versamune HPV

TIPRANKS
·
07 Mar

PDS Biotech Initiates Versatile-003 Phase 3 Clinical Trial Evaluating Versamune® Hpv in Hpv16-Positive Head and Neck Cancer

THOMSON REUTERS
·
07 Mar

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

GlobeNewswire
·
07 Mar

PDS Biotechnology Launches Registered Direct Offering; Shares Up

MT Newswires Live
·
28 Feb

PDS Biotechnology prices 7.33M shares at $1.50 in registered direct offering

TIPRANKS
·
27 Feb

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
27 Feb

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Feb

PDS Biotechnology announces circulating tumor DNA results for Versamune HPV

TIPRANKS
·
24 Feb

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

GlobeNewswire
·
24 Feb

PDS Biotechnology Corp - Biotech to Initiate Versatile-003 Phase 3 Trial in Q1 2025

THOMSON REUTERS
·
05 Feb

PDS Biotechnology Corp - Biotech on Track to Initiate Site Activation in Q1 2025

THOMSON REUTERS
·
05 Feb

PDS Biotech Reaffirms Guidance for First Quarter Initiation of Versatile-003 Phase 3 Clinical Trial in Hpv16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

THOMSON REUTERS
·
05 Feb

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswire
·
05 Feb

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Dec 2024

PDS Biotechnology reports inducement grant under Nasdaq listing rule

TIPRANKS
·
06 Dec 2024

BRIEF-PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
06 Dec 2024

B. Riley Cuts Price Target on PDS Biotechnology to $7 From $9, Keeps Buy Rating

MT Newswires Live
·
25 Nov 2024

PDS Biotechnology Corp : B. Riley Cuts Target Price to $7 From $9

THOMSON REUTERS
·
25 Nov 2024